05:27 PM EDT, 09/10/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) said late Wednesday that its new clinical data from its daraxonrasib program is underscoring the therapy's promise in treating metastatic pancreatic ductal adenocarcinoma.

According to the company, phase 1 trial results demonstrated sustained responses in previously treated patients and promising efficacy in newly diagnosed cases, both with daraxonrasib alone and alongside chemotherapy.

The company noted, in second-line RAS-mutant PDAC, daraxonrasib monotherapy achieved response rates of up to 35% and a median overall survival of 15.6 months.

Initial first-line findings showed a 47% response rate with monotherapy and 55% in combination with gemcitabine plus nab-paclitaxel, with safety profiles remaining broadly consistent, it added.

The company plans to begin RASolute 303, a global Phase 3 trial of daraxonrasib in first-line metastatic PDAC, in Q4, 2025.

Revolution Medicines ( RVMD ) shares jumped nearly 10% in recent after-hours activity.